Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of Ferrostatin-1 on Vocal Folds in Aging Rats.

The Laryngoscope·2026
Same author

Patterns of complementary and alternative medicine use and factors influencing its utilization in thyroid cancer: findings from the MASTER study.

BMC complementary medicine and therapies·2026
Same author

Decoupling Moisture and Hydrogen Barrier Properties in Silicon Nitride Films Deposited by Plasma-Enhanced Atomic Layer Deposition at 100 °C via Precursor-Defined Bonding Networks.

ACS applied materials & interfaces·2026
Same author

KASL clinical practice guidelines for management of chronic hepatitis B Endorsed by the East Asia Liver Alliance (EALA).

Clinical and molecular hepatology·2026
Same author

Risk of Intrahepatic and Extrahepatic Cancers in Hepatitis C Virus Infection: A Nationwide Cohort Study in Korea, 2005-2023.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Comprehensive Management of Diabetic Foot Ulcers: Current Evidence and Practice.

Journal of diabetes·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
Same journal

Neoadjuvant Immunotherapy-Based Treatment Versus Chemotherapy Alone in Resectable Locally Advanced dMMR/MSI-H Gastric Cancer: A Real-World Study with Meta-Analysis.

Cancers·2026
See all related articles

Related Experiment Video

Updated: Jan 11, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.8K

Diagnostic Models for Predicting Follicular Thyroid Carcinomas Using Circulating Plasma MicroRNAs.

Sin Woo Kang1, Ji Min Kim2, Sung-Chan Shin1

  • 1Department of Otorhinolaryngology-Head and Neck Surgery, College of Medicine, Pusan National University and Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea.

Cancers
|November 13, 2025
PubMed
Summary
This summary is machine-generated.

A novel four-microRNA signature in plasma can accurately differentiate follicular thyroid carcinoma (FC) from follicular thyroid adenoma (FA), potentially reducing the need for diagnostic thyroidectomies.

Keywords:
circulating miRNAdiagnosisfollicular thyroid carcinoma

More Related Videos

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

16.1K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.9K

Related Experiment Videos

Last Updated: Jan 11, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.8K
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

16.1K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.9K

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Diagnostics

Background:

  • Follicular thyroid carcinoma (FC) presents diagnostic challenges with fine-needle aspiration (FNA), often necessitating thyroidectomy.
  • Circulating microRNAs (miRNAs) are emerging biomarkers for cancer diagnosis.
  • This study aimed to assess plasma miRNAs for differentiating FC from follicular thyroid adenoma (FA).

Purpose of the Study:

  • To evaluate the diagnostic utility of plasma miRNAs for distinguishing FC from FA.
  • To develop a predictive model for FC detection using circulating miRNAs.
  • To potentially reduce unnecessary thyroidectomies and invasive procedures.

Main Methods:

  • Retrospective observational study of 90 patients diagnosed with FC or FA.
  • Microarray analysis to identify novel plasma miRNAs.
  • TaqMan qRT-PCR and logistic regression for predictive model development and validation.

Main Results:

  • A four-miRNA signature (miR-6085, miR-146b-5p, miR-221, miR-222) was identified.
  • The model demonstrated high diagnostic value with an AUC of 0.928.
  • Validation showed 76.2% accuracy in differentiating FC from FA.

Conclusions:

  • A plasma-based four-miRNA model offers high sensitivity and specificity for FC diagnosis.
  • This miRNA signature could serve as a valuable non-invasive tool for FC differentiation.
  • The findings suggest a potential reduction in diagnostic thyroidectomies.